BRPI0513359A - tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina - Google Patents
tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotoninaInfo
- Publication number
- BRPI0513359A BRPI0513359A BRPI0513359-9A BRPI0513359A BRPI0513359A BR PI0513359 A BRPI0513359 A BR PI0513359A BR PI0513359 A BRPI0513359 A BR PI0513359A BR PI0513359 A BRPI0513359 A BR PI0513359A
- Authority
- BR
- Brazil
- Prior art keywords
- pyridinyl
- quinolinyl
- quinazinyl
- benzo
- serotonin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/18—Aralkyl radicals
- C07D217/20—Aralkyl radicals with oxygen atoms directly attached to the aromatic ring of said aralkyl radical, e.g. papaverine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
TETRAIDROISOQUINOLINAS SUBSTITUìDAS POR ARILA E HETEROARILA E USO DESTES PARA BLOQUEAR A RECAPTAçãO DE NOREPINEFRINA, DOPAMINA, E SEROTONINA. A presente invenção refere-se aos compostos da presente invenção que são representados pela estrutura química encontrada na Fórmula (I): em que: o átomo de carbono designado * está na configuração R ou S; e X é um carbociclo bicíclico fundido ou heterociclo selecionado do grupo que consiste em benzofuranila, benzo¢b!tiofenila, benzoisotiazolila, benzoisoxazolila, indazolila, indolila, isoindolila, indolizinila, benzoimidazolila, benzooxazolila, benzotiazolila, benzotriazolila, imidazo¢1 ,2-a! piridinila, pirazol¢1 .5-a! piridinila, ¢1 ,2,4!triazol¢4,3-a!piridinila, tieno¢2,3-b! piridinila, tieno ¢3,2-b! piridinila, 1 H-pirrol¢2,3-b!piridinila, indenila, indanila, diidrobenzocicloeptenila, tetraidrobenzocicloeptenila, diidrobenzotiofenila, diidrobenzofuranila, indolinila, naftila, tetraidronaifila, quinolinila, isoquinolinila, 4H-quinolizinila, 9aH-quinolizinila, quinazolinila, cinolinila, ftalazinila, quinoxalinila, benzo ¢1 ,2,3!triazinila, benzo¢1 ,2,4!triazinila, 2H- cromenila, 4H-cromenila, e um carbociclo bicíclico fundido ou heterociclo bicíclico fundido opcionalmente substituído por substituintes (número 1 a 4) como definido em R¬ 14¬com R¬ 1¬, R¬ 2¬, R¬ 3¬, R¬ 4¬, R¬ 5¬, R¬ 6¬ R¬ 7¬, R¬ 8¬, e R¬ 14¬ definidos aqui.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58844804P | 2004-07-15 | 2004-07-15 | |
PCT/US2005/025193 WO2006020049A2 (en) | 2004-07-15 | 2005-07-15 | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0513359A true BRPI0513359A (pt) | 2008-05-06 |
Family
ID=35907927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0513359-9A BRPI0513359A (pt) | 2004-07-15 | 2005-07-15 | tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina |
Country Status (18)
Country | Link |
---|---|
US (7) | US20060063766A1 (pt) |
EP (1) | EP1778639B1 (pt) |
JP (2) | JP5007226B2 (pt) |
KR (2) | KR101389246B1 (pt) |
CN (2) | CN101119969B (pt) |
AU (1) | AU2005274927B2 (pt) |
BR (1) | BRPI0513359A (pt) |
CA (1) | CA2573271C (pt) |
GE (1) | GEP20094640B (pt) |
HK (1) | HK1199253A1 (pt) |
IL (1) | IL180349A (pt) |
MX (1) | MX2007000428A (pt) |
NO (1) | NO20070877L (pt) |
NZ (1) | NZ552397A (pt) |
RU (1) | RU2388751C2 (pt) |
UA (1) | UA91341C2 (pt) |
WO (1) | WO2006020049A2 (pt) |
ZA (1) | ZA200701232B (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2304984T3 (es) * | 1999-11-03 | 2008-11-01 | Amr Technology, Inc. | Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina. |
CN100430401C (zh) * | 2000-07-11 | 2008-11-05 | Amr科技公司 | 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途 |
CN101119969B (zh) * | 2004-07-15 | 2014-04-09 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用 |
US20060111385A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
US20060111393A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
US20060111394A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
KR20060059728A (ko) * | 2004-11-29 | 2006-06-02 | 삼성에스디아이 주식회사 | 액정 표시 장치 및 그 제조 방법 |
JP5258561B2 (ja) * | 2005-07-15 | 2013-08-07 | アルバニー モレキュラー リサーチ, インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
WO2007095756A1 (en) * | 2006-02-27 | 2007-08-30 | Clera Inc. | Novel central-nervous system acting compounds and methods for the treatment of cns disorders |
WO2007132841A1 (ja) | 2006-05-16 | 2007-11-22 | Takeda Pharmaceutical Company Limited | 縮合複素環化合物およびその用途 |
CN101437814A (zh) * | 2006-05-31 | 2009-05-20 | 弗·哈夫曼-拉罗切有限公司 | 作为单胺再摄取抑制剂的苯并氮杂衍生物 |
CN101641090B (zh) * | 2006-12-19 | 2012-12-05 | 亚勒斯有限公司 | 莫达非尼在制备治疗多动腿综合征的药物中的应用 |
WO2009063992A1 (ja) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
WO2009118765A2 (en) * | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Novel monoamine re-uptake inhibitor |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
AR071997A1 (es) * | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
AR072297A1 (es) | 2008-06-27 | 2010-08-18 | Novartis Ag | Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona. |
US8193363B2 (en) * | 2008-08-29 | 2012-06-05 | Astrazeneca Ab | Compounds suitable as precursors to compounds that are useful for imaging amyloid deposits |
JP5770102B2 (ja) * | 2008-12-19 | 2015-08-26 | ジェネンテック, インコーポレイテッド | 複素環化合物と使用方法 |
ES2528404T3 (es) * | 2009-05-12 | 2015-02-10 | Bristol-Myers Squibb Company | Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos |
ES2446971T3 (es) * | 2009-05-12 | 2014-03-11 | Albany Molecular Research, Inc. | Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso |
ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
JP5763313B2 (ja) * | 2009-09-03 | 2015-08-12 | 富山化学工業株式会社 | 2−(1−ベンゾチオフェン−5−イル)エタノールの製造法 |
WO2012024397A2 (en) | 2010-08-17 | 2012-02-23 | Albany Molecular Research, Inc. | 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
US9073881B2 (en) | 2011-09-23 | 2015-07-07 | Hoffmann-La Roche Inc. | Benzoic acid derivatives |
EP2760870B1 (en) | 2011-09-27 | 2016-05-04 | Bristol-Myers Squibb Company | Substituted bicyclic heteroaryl compounds |
TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
CA2886117C (en) * | 2012-10-05 | 2022-05-31 | Merck Sharp & Dohme Corp. | Indoline compounds and their use as aldosterone synthase inhibitors |
WO2014159501A2 (en) * | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Processes for preparing tetrahydroisoquinolines |
CN104402816A (zh) * | 2014-10-28 | 2015-03-11 | 常州大学 | 一种苯并吡啶甲酸的合成方法 |
JP6929857B2 (ja) * | 2016-01-15 | 2021-09-01 | ファイザー・インク | 6,7,8,9−テトラヒドロ−5H−ピリド[2,3−d]アゼピンドーパミンD3リガンド |
JP6908623B2 (ja) * | 2016-04-13 | 2021-07-28 | ユーシービー バイオファルマ エスアールエル | テトラヒドロイソキノリン誘導体 |
US20190218214A1 (en) * | 2016-09-14 | 2019-07-18 | Vanderbilt University | Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof |
WO2018065288A1 (de) | 2016-10-07 | 2018-04-12 | Bayer Cropscience Aktiengesellschaft | 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz |
US11083199B2 (en) | 2017-01-10 | 2021-08-10 | Bayer Aktiengesellschaft | Heterocycle derivatives as pesticides |
US11058115B2 (en) | 2017-01-10 | 2021-07-13 | Bayer Aktiengesellschaft | Heterocycle derivatives as pesticides |
CN107141202A (zh) * | 2017-06-29 | 2017-09-08 | 白银龙铭化工科技有限公司 | 7‑溴‑3,4‑二氢‑1(2h)‑萘酮化合物的合成方法 |
JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
WO2019137985A1 (en) * | 2018-01-10 | 2019-07-18 | Allinky Biopharma | Tetrahydroisoquinoline compounds |
BR112021006843A2 (pt) * | 2018-10-10 | 2021-07-13 | Albert Einstein College Of Medicine | benzoxazol e compostos relacionados úteis como moduladores de autofagia mediada por chaperona |
CN109400453B (zh) * | 2018-12-13 | 2021-04-27 | 河南师范大学 | 一种2,6-二溴苯甲醛的制备方法 |
CN114702428B (zh) * | 2019-12-09 | 2023-11-28 | 苏州恩华生物医药科技有限公司 | 连双环结构sigma-1受体抑制剂 |
CN114315796B (zh) * | 2021-12-30 | 2024-03-26 | 中国药科大学 | 用作hpk1激酶抑制剂的化合物及其制备方法和应用 |
Family Cites Families (305)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3666763A (en) * | 1970-01-06 | 1972-05-30 | Hoffmann La Roche | 4-phenyl isoquinolines and process for preparing same |
US3947456A (en) * | 1970-01-06 | 1976-03-30 | Hoffman-La Roche Inc. | Substituted 4-phenyl isoquinolines |
CH527194A (de) | 1970-01-06 | 1972-08-31 | Hoffmann La Roche | Verfahren zur Herstellung von Isochinolin-Derivaten |
JPS5223083B2 (pt) | 1972-03-31 | 1977-06-22 | ||
JPS5223083Y2 (pt) | 1972-06-23 | 1977-05-26 | ||
GB1504424A (en) * | 1975-08-09 | 1978-03-22 | Beecham Group Ltd | Isoquinoline-derived aminoethers |
US4340600A (en) * | 1980-05-22 | 1982-07-20 | Smithkline Corporation | Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines |
DE3333994A1 (de) * | 1983-09-21 | 1985-04-04 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyridoindolderivate, verfahren zu ihrer herstellung und ihre verwendung |
US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
ZA885824B (en) * | 1987-08-14 | 1989-04-26 | Merrell Dow Pharma | Novel antidepressants |
EP0360390A1 (en) | 1988-07-25 | 1990-03-28 | Glaxo Group Limited | Spirolactam derivatives |
WO1990005525A1 (en) | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
FI895821A0 (fi) | 1988-12-07 | 1989-12-05 | Wellcome Found | Farmaceutiskt aktiva cns foereningar. |
US4902710A (en) * | 1988-12-14 | 1990-02-20 | Eli Lilly And Company | Serotonin and norepinephrine uptake inhibitors |
US5114976A (en) * | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
EP0380223A1 (en) | 1989-01-17 | 1990-08-01 | Konica Corporation | Colour filter and process for producing the same |
JPH02281203A (ja) | 1989-04-21 | 1990-11-16 | Konica Corp | カラーフィルター |
BG49761A1 (en) | 1989-04-24 | 1992-02-14 | Vissh Khim T I | 4- (4'- chalophenyl)- 2- methyl- 1, 2, 3, 4- tetrahydroisohinolines and method for its preparation |
US5164372A (en) | 1989-04-28 | 1992-11-17 | Fujisawa Pharmaceutical Company, Ltd. | Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same |
AU6368090A (en) | 1989-10-03 | 1991-04-11 | Warner-Lambert Company | Substituted carboxytetrahydroisoquinolines and derivatives thereof having pharmaceutical activity |
FI97540C (fi) | 1989-11-06 | 1997-01-10 | Sanofi Sa | Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi |
FR2654726B1 (fr) | 1989-11-23 | 1992-02-14 | Rhone Poulenc Sante | Nouveaux derives de l'isoindolone et leur preparation. |
FR2654725B1 (fr) | 1989-11-23 | 1992-02-14 | Rhone Poulenc Sante | Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent. |
GB8929070D0 (en) | 1989-12-22 | 1990-02-28 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
UA41251C2 (uk) | 1990-01-04 | 2001-09-17 | Пфайзер, Інк. | Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі |
US5232929A (en) | 1990-11-28 | 1993-08-03 | Pfizer Inc. | 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use |
WO1991012266A1 (en) | 1990-02-15 | 1991-08-22 | Fujisawa Pharmaceutical Co., Ltd. | Peptide compound |
US5447947A (en) | 1990-02-26 | 1995-09-05 | Arc 1 | Compositions and methods of treatment of sympathetically maintained pain |
HUT62891A (en) | 1990-06-01 | 1993-06-28 | Pfizer | Process for producing 3-amino-2-arylquinuclidine compounds and pharmaceuticql composition comprising such compounds |
AU660416B2 (en) | 1990-07-23 | 1995-06-29 | Pfizer Inc. | Quinuclidine derivatives |
DE69109125T2 (de) | 1990-09-28 | 1995-09-28 | Pfizer | Ringverknüpfte analoge von stickstoffenthaltenden nichtaromatischen heterocyclen. |
GB9023116D0 (en) | 1990-10-24 | 1990-12-05 | Fujisawa Pharmaceutical Co | Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same |
JPH04193867A (ja) | 1990-11-23 | 1992-07-13 | Nippon Shinyaku Co Ltd | イソキノリノール誘導体及び医薬 |
DK0498069T3 (da) | 1990-12-21 | 1995-12-04 | Fujisawa Pharmaceutical Co | Ny anvendelse af peptidderivat |
EP0566589A1 (en) | 1991-01-10 | 1993-10-27 | Pfizer Inc. | N-alkyl quinuclidinium salts as substance p antagonists |
DE69220258T2 (de) | 1991-02-11 | 1997-12-18 | Merck Sharp & Dohme | Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung |
JPH082901B2 (ja) | 1991-03-01 | 1996-01-17 | ファイザー・インコーポレーテッド | 1−アザビシクロ[3.2.2ノナン−3−アミン誘導体類 |
CZ293955B6 (cs) | 1991-03-26 | 2004-08-18 | Pfizeráinc | Postup přípravy substituovaných piperidinů |
FR2677361A1 (fr) | 1991-06-04 | 1992-12-11 | Adir | Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2676055B1 (fr) | 1991-05-03 | 1993-09-03 | Sanofi Elf | Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2676053B1 (fr) | 1991-05-03 | 1993-08-27 | Sanofi Elf | Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2676446B1 (fr) | 1991-05-17 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
FR2676443B1 (fr) | 1991-05-17 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux derives de perhydroisoindole et leur preparation. |
FR2676447B1 (fr) | 1991-05-17 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux derives du thiopyranopyrrole et leur preparation. |
FR2676442B1 (fr) | 1991-05-17 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
WO1992020661A1 (en) | 1991-05-22 | 1992-11-26 | Merck & Co., Inc. | N, n-diacylpiperazines |
ATE211743T1 (de) | 1991-05-22 | 2002-01-15 | Pfizer | Substituierte 3-aminochinuclidine |
DE69208877T2 (de) | 1991-05-31 | 1996-07-25 | Pfizer | Chinuclidinderivate |
GB9113219D0 (en) | 1991-06-19 | 1991-08-07 | Fujisawa Pharmaceutical Co | Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same |
DE9290083U1 (de) | 1991-06-20 | 1994-02-17 | Pfizer | Fluoralkoxybenzylamino-Derivate von stickstoffhaltigen Heterocyclen |
TW202432B (pt) | 1991-06-21 | 1993-03-21 | Pfizer | |
US5288730A (en) | 1991-06-24 | 1994-02-22 | Merck Sharp & Dohme Limited | Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy |
EP0536817A1 (en) | 1991-07-05 | 1993-04-14 | MERCK SHARP & DOHME LTD. | Azabicyclic compounds as tachykinin antagonists |
US5472978A (en) | 1991-07-05 | 1995-12-05 | Merck Sharp & Dohme Ltd. | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
EP0522808A3 (en) | 1991-07-05 | 1993-01-27 | MERCK SHARP & DOHME LTD. | Aromatic compounds, pharmaceutical compositions containing them and their use in therapy |
EP0593615B1 (en) | 1991-07-10 | 1996-01-31 | MERCK SHARP & DOHME LTD. | Aromatic compounds, compositions containing them and their use in therapy |
WO1993001159A1 (en) | 1991-07-10 | 1993-01-21 | Merck Sharp & Dohme Limited | Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy |
MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
JPH06510034A (ja) | 1991-08-20 | 1994-11-10 | メルク シヤープ エンド ドーム リミテツド | アザ環式化合物、それらの製造方法、及びそれらを含む医薬組成物 |
DE69231395T3 (de) | 1991-09-20 | 2005-07-21 | Glaxo Group Ltd., Greenford | Neue medizinische Indikation für Tachykinin-Antagonisten |
BR9206500A (pt) | 1991-09-26 | 1995-10-03 | Pfizer | Heterociclos contendo, nitrogênio tricíclico condensado como antagonistas de substancia receptora P |
WO1993009116A1 (en) | 1991-11-07 | 1993-05-13 | Yoshitomi Pharmaceutical Industries, Ltd. | Quinuclidine compound and medicinal use thereof |
JP2614408B2 (ja) | 1991-11-12 | 1997-05-28 | ファイザー・インコーポレーテッド | サブスタンスp受容体アンタゴニストとしての非環式エチレンジアミン誘導体 |
CA2083891A1 (en) | 1991-12-03 | 1993-06-04 | Angus Murray Macleod | Heterocyclic compounds, compositions containing them and their use in therapy |
GB9200535D0 (en) | 1992-01-10 | 1992-02-26 | Fujisawa Pharmaceutical Co | New compound |
GB9201179D0 (en) | 1992-01-21 | 1992-03-11 | Glaxo Group Ltd | Chemical compounds |
US5241065A (en) | 1992-02-25 | 1993-08-31 | Schering Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity |
US5328927A (en) | 1992-03-03 | 1994-07-12 | Merck Sharpe & Dohme, Ltd. | Hetercyclic compounds, processes for their preparation and pharmaceutical compositions containing them |
US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
JP2656702B2 (ja) | 1992-03-23 | 1997-09-24 | ファイザー製薬株式会社 | ペプチド性キヌクリジン |
FR2689888B1 (fr) | 1992-04-10 | 1994-06-10 | Rhone Poulenc Rorer Sa | Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent. |
AU675786B2 (en) | 1992-04-15 | 1997-02-20 | Merck Sharp & Dohme Limited | Azacyclic compounds |
GB2266529A (en) | 1992-05-01 | 1993-11-03 | Merck Sharp & Dohme | Tetrahydroisoquinoline derivatives |
CA2134964C (en) | 1992-05-18 | 1997-12-30 | Manoj C. Desai | Bridged aza-bicyclic derivatives as substance p antagonists |
GB9211193D0 (en) | 1992-05-27 | 1992-07-08 | Merck Sharp & Dohme | Therapeutic agents |
IL106142A (en) | 1992-06-29 | 1997-03-18 | Merck & Co Inc | Morpholine and thiomorpholine tachykinin receptor antagonists, their preparation and pharmaceutical compositions containing them |
WO1994001402A1 (en) | 1992-07-13 | 1994-01-20 | Merck Sharp & Dohme Limited | Heterocyclic amide derivatives as tachykinin derivatives |
JPH07509133A (ja) | 1992-07-17 | 1995-10-12 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 動物疾患の処置のための方法および剤 |
GB2268931A (en) | 1992-07-22 | 1994-01-26 | Merck Sharp & Dohme | Azabicyclic tachykinin-receptor antagonists |
JPH07508993A (ja) | 1992-07-28 | 1995-10-05 | メルク シヤープ エンド ドーム リミテツド | アザサイクリック化合物 |
GB2269170A (en) | 1992-07-29 | 1994-02-02 | Merck Sharp & Dohme | Azatricyclic tachykinin antagonists |
WO1994003429A1 (en) | 1992-07-31 | 1994-02-17 | Merck Sharp & Dohme Limited | Substituted amines as tachykinin receptor antagonists |
EP0654029A1 (en) | 1992-08-04 | 1995-05-24 | Pfizer Inc. | 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists |
GB9216911D0 (en) | 1992-08-10 | 1992-09-23 | Merck Sharp & Dohme | Therapeutic agents |
ES2153841T3 (es) | 1992-08-13 | 2001-03-16 | Warner Lambert Co | Antagonistas de la taciquinina. |
US5212185A (en) | 1992-08-14 | 1993-05-18 | G. D. Searle & Co. | Piperidinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension |
EP1114823A3 (en) | 1992-08-19 | 2001-07-18 | Pfizer Inc. | Substituted benzylamino nitrogen containing non-aromatic heterocycles |
NO179904C (no) | 1992-09-04 | 1997-01-08 | Takeda Chemical Industries Ltd | Kondenserte heterocykliske forbindelser og deres anvendelse |
US5563161A (en) | 1992-09-10 | 1996-10-08 | Merck Sharp & Dohme Ltd. | Alcohols and ethers with aromatic substituents as tachykinin-antagonists |
GB9220286D0 (en) | 1992-09-25 | 1992-11-11 | Merck Sharp & Dohme | Therapeutic agents |
GB2271566A (en) | 1992-10-14 | 1994-04-20 | Merck & Co Inc | HIV integrase inhibitors |
JP2656699B2 (ja) | 1992-10-21 | 1997-09-24 | ファイザー製薬株式会社 | 置換ベンジルアミノキヌクリジン |
GB9222262D0 (en) | 1992-10-23 | 1992-12-09 | Merck Sharp & Dohme | Therapeutic agents |
GB9222486D0 (en) | 1992-10-26 | 1992-12-09 | Merck Sharp & Dohme | Therapeutic agents |
JP2656700B2 (ja) | 1992-10-28 | 1997-09-24 | ファイザー製薬株式会社 | 置換キヌクリジン誘導体 |
DE69327541T2 (de) | 1992-10-28 | 2000-08-10 | Merck Sharp & Dohme | 4-arylmethyloxymethyl piperidine als tachykinin antagonisten |
AU5342894A (en) | 1992-10-30 | 1994-05-24 | Merck Sharp & Dohme Limited | Tachykinin antagonists |
US5886009A (en) | 1992-11-12 | 1999-03-23 | Pfizer Inc. | Quinuclidine derivative as a substance P antagonist |
US5261188A (en) | 1992-11-23 | 1993-11-16 | The Standard Products Company | Belt weatherstrip with bulb |
JPH06153997A (ja) | 1992-11-27 | 1994-06-03 | Canon Inc | 検出信号増幅による標的核酸の検出方法 |
AU5169693A (en) | 1992-12-10 | 1994-07-04 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists |
CA2150951A1 (en) | 1992-12-14 | 1994-06-23 | Angus Murray Macleod | 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists |
GB9226581D0 (en) | 1992-12-21 | 1993-02-17 | Merck Sharp & Dohme | Therapeutic agents |
DK154192D0 (da) * | 1992-12-23 | 1992-12-23 | Neurosearch As | Heterocycliske forbindelser |
GB9300051D0 (en) | 1993-01-04 | 1993-03-03 | Merck Sharp & Dohme | Therapeutic agents |
US5466689A (en) | 1993-02-08 | 1995-11-14 | Takeda Chemical Industries, Ltd. | Morpholine derivatives and their use |
EP0683767B1 (en) | 1993-02-18 | 1998-06-03 | MERCK SHARP & DOHME LTD. | Azacyclic compounds, compositions containing them and their use as tachykinin antagonists |
US5674889A (en) | 1993-02-22 | 1997-10-07 | Merck, Sharp & Dohme, Ltd. | Aromatic compounds, compositions containing them and their use in therapy |
US5688806A (en) | 1993-03-04 | 1997-11-18 | Pfizer Inc. | Spiroazacyclic derivatives as substance P antagonists |
WO1994022826A1 (en) | 1993-04-07 | 1994-10-13 | Otsuka Pharmaceutical Co., Ltd. | Peripheral vasodilating agent containing n-acylated 4-amino piperidine derivatives as active ingredients |
CN1081635C (zh) | 1993-05-06 | 2002-03-27 | 默里尔药物公司 | 取代的吡咯烷 -3-基-烷基-哌啶 |
IL109646A0 (en) | 1993-05-19 | 1994-08-26 | Pfizer | Heteroatom substituted alkyl benzylamino-quinuclidines |
CA2163995A1 (en) | 1993-06-07 | 1994-12-22 | Malcolm Maccoss | Spiro-substituted azacycles as neurokinin antagonists |
EP0634402A1 (en) | 1993-07-14 | 1995-01-18 | Takeda Chemical Industries, Ltd. | Isochinolinone derivatives, their production and use |
US5869499A (en) | 1993-07-15 | 1999-02-09 | Pfizer Inc | Benzyloxyquinuclidines as substance P antagonists |
GB9315808D0 (en) | 1993-07-30 | 1993-09-15 | Merck Sharp & Dohme | Therapeutic agents |
TW365603B (en) | 1993-07-30 | 1999-08-01 | Rhone Poulenc Rorer Sa | Novel perhydroisoindole derivatives, their preparation and pharmaceutical compositions which contain them |
GB9317987D0 (en) | 1993-08-26 | 1993-10-13 | Glaxo Group Ltd | Chemical compounds |
EP0719253B1 (en) | 1993-09-17 | 2004-04-28 | Pfizer Inc. | 3-amino-5-carboxy-substituted piperidines and 3-amino-4-carboxy-substituted pyrrolidines as tachykinin antagonists |
AU7082194A (en) | 1993-09-17 | 1995-04-03 | Pfizer Inc. | Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds |
IL111002A (en) | 1993-09-22 | 1998-09-24 | Glaxo Group Ltd | History of piperidine, their preparation and the pharmaceutical preparations containing them |
AU7947594A (en) | 1993-10-27 | 1995-05-22 | Merck Sharp & Dohme Limited | Substituted amides as tachykinin antagonists |
US6403577B1 (en) | 1993-11-17 | 2002-06-11 | Eli Lilly And Company | Hexamethyleneiminyl tachykinin receptor antagonists |
IT1271462B (it) | 1993-12-03 | 1997-05-28 | Menarini Farma Ind | Antagonisti delle tachichinine,procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche. |
IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
EP0736007A4 (en) | 1993-12-21 | 1997-03-19 | Lilly Co Eli | NON-PEPTIDE ANTAGONISTS OF TACHYKININ RECEPTORS |
PL179435B1 (pl) | 1993-12-29 | 2000-09-29 | Pfizer | Diazabicykliczni antagonisci neurokininy PL |
PL181214B1 (pl) | 1993-12-29 | 2001-06-29 | Merck Sharp & Dohme | Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne |
WO1995020575A1 (en) | 1994-01-28 | 1995-08-03 | Merck Sharp & Dohme Limited | Aralkylamino substituted azacyclic therapeutic agents |
GB9402688D0 (en) | 1994-02-11 | 1994-04-06 | Merck Sharp & Dohme | Therapeutic agents |
US5610165A (en) | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
FR2718136B1 (fr) | 1994-03-29 | 1996-06-21 | Sanofi Sa | Composés aromatiques aminés, procédé pour leur obtention et compositions pharmaceutiques les contenant. |
US5610145A (en) | 1994-04-15 | 1997-03-11 | Warner-Lambert Company | Tachykinin antagonists |
US5607939A (en) * | 1994-04-28 | 1997-03-04 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
NZ270985A (en) | 1994-04-29 | 1997-06-24 | Lilly Co Eli | Substituted benzimidazole derivatives; medicaments and preparation of medicaments |
EP0758329A1 (en) | 1994-05-05 | 1997-02-19 | MERCK SHARP & DOHME LTD. | Morpholine derivatives and their use as antagonists of tachikinins |
EE9600186A (et) | 1994-05-07 | 1997-08-15 | Boehringer Ingelheim Kg | Neurokiniini (tahhüülkiniini) antagonistid |
CA2187531A1 (en) | 1994-06-06 | 1995-12-14 | David Christopher Horwell | Tachykinin (nk1) receptor antagonists |
EP0686629A3 (en) | 1994-06-10 | 1999-02-10 | Eli Lilly And Company | Cyclohexyl tachykinine receptor antagonists |
CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
US6162809A (en) | 1994-07-10 | 2000-12-19 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Pyridylthio compounds for controlling helicobacter bacteria |
JPH10502640A (ja) | 1994-07-12 | 1998-03-10 | イーライ・リリー・アンド・カンパニー | 異項環タキキニン受容体拮抗物質 |
DE4425612A1 (de) | 1994-07-20 | 1996-04-04 | Bayer Ag | 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone |
CA2154116A1 (en) | 1994-07-22 | 1996-01-23 | Philip Arthur Hipskind | 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists |
GB9415997D0 (en) | 1994-08-08 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
GB9415996D0 (en) | 1994-08-08 | 1994-09-28 | Merck Sharp & Dohme | Therapeutic agents |
TW432061B (en) | 1994-08-09 | 2001-05-01 | Pfizer Res & Dev | Lactams |
CA2195972A1 (en) | 1994-08-15 | 1996-02-22 | Merck Sharp & Dohme Limited | Morpholine derivatives and their use as therapeutic agents |
ATE177095T1 (de) | 1994-08-25 | 1999-03-15 | Merrell Pharma Inc | Substituierte piperidine für die behandlung von allergischen krankheiten |
DE69405864T2 (de) | 1994-08-29 | 1998-03-26 | Akzo Nobel Nv | Verfahren zur Herstellung von quaternären Diestern |
GB9417956D0 (en) | 1994-09-02 | 1994-10-26 | Merck Sharp & Dohme | Therapeutic agents |
GB9418545D0 (en) | 1994-09-15 | 1994-11-02 | Merck Sharp & Dohme | Therapeutic agents |
US5457107A (en) | 1994-09-16 | 1995-10-10 | Merck & Co., Inc. | Polymorphic form of a tachykinin receptor antagonist |
JPH10506399A (ja) | 1994-09-30 | 1998-06-23 | ノバルティス アクチェンゲゼルシャフト | 1−アシル−4−マリファチルアミノピペリジン化合物 |
TW397825B (en) | 1994-10-14 | 2000-07-11 | Novartis Ag | Aroyl-piperidine derivatives |
FR2725986B1 (fr) | 1994-10-21 | 1996-11-29 | Adir | Nouveaux derives de piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE69534213T2 (de) | 1994-10-25 | 2006-01-12 | Astrazeneca Ab | Therapeutisch wirksame Heterocyclen |
GB9421709D0 (en) | 1994-10-27 | 1994-12-14 | Zeneca Ltd | Therapeutic compounds |
EP0714891A1 (en) | 1994-11-22 | 1996-06-05 | Eli Lilly And Company | Heterocyclic tachykinin receptor antagonists |
FR2727411B1 (fr) | 1994-11-30 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent |
IL116323A0 (en) | 1994-12-13 | 1996-03-31 | Sandoz Ag | Tachykinin antagonists their preparation and pharmaceutical compositions containing them |
GB9426103D0 (en) | 1994-12-23 | 1995-02-22 | Merck Sharp & Dohme | Therapeutic agents |
AU4437896A (en) | 1995-01-12 | 1996-07-31 | Glaxo Group Limited | Piperidine derivatives having tachykinin antagonist activity |
FR2729951B1 (fr) | 1995-01-30 | 1997-04-18 | Sanofi Sa | Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant |
GB9505492D0 (en) | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
GB9505491D0 (en) | 1995-03-18 | 1995-05-03 | Merck Sharp & Dohme | Therapeutic agents |
US5554641A (en) | 1995-03-20 | 1996-09-10 | Horwell; David C. | Nonpeptides as tachykinin antagonists |
GB9505692D0 (en) | 1995-03-21 | 1995-05-10 | Glaxo Group Ltd | Chemical compounds |
TW394773B (en) | 1995-03-24 | 2000-06-21 | Takeda Chemical Industries Ltd | Cyclic compounds for antagonizing tachykinin receptor, substance p receptor and neurokinin a receptor, their production and pharmaceutical composition |
US5565568A (en) | 1995-04-06 | 1996-10-15 | Eli Lilly And Company | 2-acylaminopropanamides as tachykinin receptor antagonists |
CA2217006C (en) | 1995-04-13 | 2001-05-22 | Hoechst Marion Roussel, Inc. | Novel substituted piperazine derivatives having tachykinin receptor antagonists activity |
KR19990021857A (ko) | 1995-05-25 | 1999-03-25 | 후지야마 아키라 | 뉴로키닌 수용체 길항물질로서 1-벤조일-2-(인돌일-3-알킬)-피페라진 유도체 |
US5654316A (en) | 1995-06-06 | 1997-08-05 | Schering Corporation | Piperidine derivatives as neurokinin antagonists |
US5817832A (en) | 1995-06-22 | 1998-10-06 | Ciba Specialty Chemicals Corporation | Blue diketopyrrolopyrrole pigments |
GB9513118D0 (en) | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
GB9513117D0 (en) | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
GB9513121D0 (en) | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
WO1997003066A1 (en) | 1995-07-07 | 1997-01-30 | Pfizer Pharmaceuticals Inc. | Substituted benzolactam compounds as substance p antagonists |
TW340842B (en) | 1995-08-24 | 1998-09-21 | Pfizer | Substituted benzylaminopiperidine compounds |
EP0858444A4 (en) | 1995-10-18 | 1999-12-01 | Merck & Co Inc | CYCLOPENTYL-TACHYKININ RECEPTOR ANTAGONISTS |
DE19541283A1 (de) | 1995-11-06 | 1997-05-07 | Boehringer Ingelheim Kg | Neue Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
GB9523244D0 (en) | 1995-11-14 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
WO1997019084A1 (en) | 1995-11-23 | 1997-05-29 | Merck Sharp & Dohme Limited | Spiro-piperidine derivatives and their use as tachykinin antagonists |
GB9524157D0 (en) | 1995-11-25 | 1996-01-24 | Pfizer Ltd | Therapeutic agents |
RU2135494C1 (ru) | 1995-12-01 | 1999-08-27 | Санкио Компани Лимитед | Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина |
GB9525296D0 (en) | 1995-12-11 | 1996-02-07 | Merck Sharp & Dohme | Therapeutic agents |
ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
US6025355A (en) | 1997-05-19 | 2000-02-15 | Cambridge Neuroscience, Inc. | Pharmaceutically active compounds and methods of use |
AU715658B2 (en) | 1996-04-03 | 2000-02-10 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5827875A (en) | 1996-05-10 | 1998-10-27 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
US5885983A (en) | 1996-05-10 | 1999-03-23 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
EA001574B1 (ru) | 1996-06-21 | 2001-06-25 | Мерк Шарп Энд Домэ Лимитед | Производные спиропиперидина и их использование в качестве терапевтических агентов |
DE19638484A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
DE19638486A1 (de) | 1996-09-20 | 1998-03-26 | Basf Ag | Hetaroylderivate |
WO1998035939A1 (fr) | 1997-02-18 | 1998-08-20 | Sanwa Kagaku Kenkyusho Co., Ltd. | Derives de diamide malonique et utilisation de ces derniers |
US5907041A (en) | 1997-03-12 | 1999-05-25 | Rhone-Poulenc Inc. | Process for preparing pyrazole derivatives |
JPH10292008A (ja) | 1997-04-21 | 1998-11-04 | Grand Polymer:Kk | α−オレフィンの重合方法 |
DK1023265T3 (da) | 1997-10-07 | 2003-02-24 | Boehringer Ingelheim Ca Ltd | Azetidinonderivater til behandlingen af HCMV infektioner |
JP2001519328A (ja) | 1997-10-07 | 2001-10-23 | ベーリンガー インゲルハイム (カナダ) リミテッド | Hcmv感染症治療のためのアゼチジノン誘導体 |
US7041702B1 (en) | 1997-10-21 | 2006-05-09 | Scion Pharmaceuticals, Inc. | Pharmaceutically active compounds and methods of use |
US6121261A (en) * | 1997-11-19 | 2000-09-19 | Merck & Co., Inc. | Method for treating attention deficit disorder |
US6943159B1 (en) | 1998-02-18 | 2005-09-13 | Neurosearch A/S | Compounds and their use as positive AMPA receptor modulators |
US6043253A (en) | 1998-03-03 | 2000-03-28 | Merck & Co., Inc. | Fused piperidine substituted arylsulfonamides as β3-agonists |
AU5907399A (en) | 1998-09-04 | 2000-03-27 | Ciba Specialty Chemicals Holding Inc. | Process for making 2,4-dihydroxyphenyl and 2-hydroxy-4-alkoxyphenyl substituted triazine compounds |
JP2000186110A (ja) | 1998-12-21 | 2000-07-04 | Ube Ind Ltd | エチレン共重合体の製造方法 |
JP2002534488A (ja) | 1999-01-12 | 2002-10-15 | クラリアント・インターナシヨナル・リミテツド | ベンゾフェノンおよび光重合開始剤としてのその使用 |
US6664293B2 (en) | 1999-02-26 | 2003-12-16 | Fujiwawa Pharmaceutical Co., Ltd. | Amide compounds for the potentiation of cholinergic activity |
US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
JP2001026580A (ja) | 1999-05-10 | 2001-01-30 | Sumitomo Chem Co Ltd | 光学活性1−アリール−1,2,3,4−テトラヒドロイソキノリン類の製造法 |
US6562836B1 (en) | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
KR20010085555A (ko) | 1999-06-24 | 2001-09-07 | 히라이 가쯔히꼬 | 아드레날린 알파1비 수용체 길항약 |
EP1237547A2 (en) | 1999-07-09 | 2002-09-11 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
JP2001086110A (ja) | 1999-09-13 | 2001-03-30 | Toyo Commun Equip Co Ltd | 暗号化情報のパケット通信システム |
ES2304984T3 (es) * | 1999-11-03 | 2008-11-01 | Amr Technology, Inc. | Tetra-hidroisoquinolinas de sustitucion arilica y heteroarilica y su utilizacion para bloquear la recaptacion de norepinefrina, dopamina y serotonina. |
MXPA02004329A (es) | 1999-11-03 | 2005-08-26 | Amr Technology Inc | Tetrahidroisoquinolinas 4-fenil-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina. |
US7163949B1 (en) * | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
NZ519984A (en) | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
WO2001070728A1 (en) | 2000-03-23 | 2001-09-27 | Sanofi-Synthelabo | 2-[nitrogen-heterocyclic]pyrimidone derivatives |
US6506773B2 (en) | 2000-05-15 | 2003-01-14 | Darwin Discovery Ltd. | Hydroxamic and carboxylic acid derivatives |
US6664256B1 (en) | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
CN100430401C (zh) | 2000-07-11 | 2008-11-05 | Amr科技公司 | 新的4-苯基取代的四氢异喹啉类化合物及其治疗用途 |
JP2004515494A (ja) | 2000-12-07 | 2004-05-27 | アストラゼネカ・アクチエボラーグ | 治療剤 |
US6506772B1 (en) | 2000-12-15 | 2003-01-14 | Hoffmann-La Roche Inc. | Substituted [1,2,4]triazolo[1,5a]pyridine derivatives with activity as adenosine receptor ligands |
US6900220B2 (en) | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
US6911453B2 (en) * | 2001-12-05 | 2005-06-28 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium, process for their preparation, their use as a medicament, and medicament containing them |
US6974803B2 (en) | 2001-12-06 | 2005-12-13 | Pfizer Inc | Pharmaceutical combination |
US6703405B2 (en) | 2001-12-22 | 2004-03-09 | Aventis Pharma Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolinium salts, process for their preparation, their use as a medicament, and medicament containing them |
US20050261298A1 (en) | 2002-01-18 | 2005-11-24 | David Solow-Cordero | Methods of treating conditions associated with an Edg-7 receptor |
US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
EP1676844A1 (en) | 2004-12-28 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
WO2003077874A2 (en) | 2002-03-13 | 2003-09-25 | The University Of Tennessee Research Foundation | Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
DK1852415T3 (da) | 2002-07-09 | 2010-01-25 | Lonza Ag | Fremgangsmåde til fremstilling af N-monosubstituerede beta-aminoalkoholer |
JP2006500350A (ja) | 2002-08-13 | 2006-01-05 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | マトリックスメタロプロテイナーゼ阻害剤としてのイソキノリン誘導体 |
BR0313724A (pt) | 2002-08-13 | 2005-06-28 | Warner Lambert Co | Derivados de azaisoquinolina como inibidores de metaloproteinase de matriz |
AU2002357644A1 (en) | 2002-09-20 | 2004-04-08 | Medisyn Technologies, Inc. | Therapeutic agents and corresponding treatments |
EP1554394B1 (en) | 2002-10-16 | 2009-12-16 | Isis Innovation Limited | Screening methods using a structural model of FIH |
GB0224557D0 (en) | 2002-10-22 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
MXPA05005829A (es) | 2002-12-02 | 2005-08-29 | Pharmacia & Upjohn Co Llc | El uso de tetrahidroisoquinolinas 4-fenil-sustituidas en el tratamiento del dolor, dolores de cabeza migranosos e incontinencia urinaria. |
AU2003283646A1 (en) | 2002-12-02 | 2004-06-23 | Pharmacia & Upjohn Company Llc | The use of aryl- and heteroaryl-substituted tetrahydroisoquinolines in the treatment of chronic and neuropathic pain, migraine headaches, and urge, stress and mixed urinary incontinence |
DE10303254B3 (de) | 2003-01-28 | 2004-09-23 | Johannes-Gutenberg-Universität Mainz | 3,3-Dimethyl-8-oxoisochinoline, Verfahren zu ihrer Herstellung, sie enthaltende pharmazeutische Zusammensetzungen und deren Verwendung |
JP2006516573A (ja) | 2003-01-31 | 2006-07-06 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての3−アミノ−4−フェニルブタン酸誘導体 |
US7241775B2 (en) | 2003-03-24 | 2007-07-10 | Sanofi-Aventis Deutschland Gmbh | Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines |
WO2004096774A1 (en) | 2003-05-01 | 2004-11-11 | Glaxo Group Limited | Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents |
US7459460B2 (en) | 2003-05-28 | 2008-12-02 | Bristol-Myers Squibb Company | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators |
AU2004253579B2 (en) | 2003-07-01 | 2010-12-23 | Biomol International L.P. | Sirt1 modulators for manipulating cells/organism lifespan/stress response |
US7459472B2 (en) | 2003-08-08 | 2008-12-02 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
CN1867331B (zh) | 2003-09-17 | 2010-05-26 | 美国政府健康及人类服务部 | 作为TNF-α调节剂的沙利度胺类似物 |
US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
JP2007008816A (ja) | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
WO2005054176A1 (en) | 2003-11-25 | 2005-06-16 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
US20050171027A1 (en) | 2003-12-29 | 2005-08-04 | President And Fellows Of Harvard College | Compositions for treating or preventing obesity and insulin resistance disorders |
EP1723134A2 (en) | 2004-02-18 | 2006-11-22 | Pfizer Products Incorporated | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline |
EP1729774A4 (en) | 2004-03-09 | 2009-05-06 | Nat Health Research Institutes | PYRROLIDINE COMPOUNDS |
WO2005095403A2 (en) | 2004-03-30 | 2005-10-13 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
EP1750706B1 (en) | 2004-06-01 | 2016-10-05 | University Of Virginia Patent Foundation | Dual small molecule inhibitors of cancer and angiogenesis |
WO2006004722A2 (en) | 2004-06-30 | 2006-01-12 | Biomol Research Laboratories, Inc. | Compositions and methods for selectively activating human sirtuins |
CN101119969B (zh) * | 2004-07-15 | 2014-04-09 | 阿尔巴尼分子研究公司 | 芳基和杂芳基取代的四氢异喹啉及其阻断去甲肾上腺素、多巴胺和血清素的重摄取的应用 |
CN101022799A (zh) | 2004-07-19 | 2007-08-22 | 约翰·霍普金斯大学 | 供免疫抑制的flt3抑制剂 |
US7211584B2 (en) | 2004-08-18 | 2007-05-01 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor ligands |
US7211585B2 (en) | 2004-08-18 | 2007-05-01 | Laboratorios Del Dr. Esteve, S.A. | 5-HT7 receptor antagonists |
DE102004046492A1 (de) | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
US20060111394A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
US20060111393A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | 4-Phenyl substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
US20060111385A1 (en) * | 2004-11-22 | 2006-05-25 | Molino Bruce F | Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof |
WO2006066197A1 (en) | 2004-12-17 | 2006-06-22 | Janssen Pharmaceutica, N.V. | Tetrahydroisoquinoline compounds for treatment of cns disorders |
US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
JP2008528510A (ja) | 2005-01-20 | 2008-07-31 | サートリス ファーマシューティカルズ, インコーポレイテッド | 紅潮および/または薬物誘発性体重増加を処置するためのサーチュイン活性化化合物の使用 |
RU2007128987A (ru) | 2005-02-15 | 2009-03-27 | Ново Нордиск А/С (DK) | 3,4-дигидро-1н-изохинолин-2-карбоновой кислоты 5-аминопиридин-2-2-иловые эфиры |
WO2006105440A2 (en) | 2005-03-30 | 2006-10-05 | Sirtris Pharmaceuticals, Inc. | Nicotinamide riboside and analogues thereof |
DE102005025625A1 (de) | 2005-06-01 | 2006-12-07 | Friedrich-Schiller-Universität Jena | Neue hochaffine Dopaminantagonisten zur Behandlung der Schizophrenie und Verfahren zu ihrer Herstellung |
JP5258561B2 (ja) * | 2005-07-15 | 2013-08-07 | アルバニー モレキュラー リサーチ, インコーポレイテッド | アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用 |
US7425633B2 (en) | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
CA2621949A1 (en) | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
AR058065A1 (es) | 2005-09-27 | 2008-01-23 | Novartis Ag | Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas. |
EA013907B1 (ru) | 2005-10-26 | 2010-08-30 | Мерк Сероно С.А. | Сульфонамидные производные и их применение для модулирования металлопротеаз |
WO2007054453A2 (en) | 2005-11-11 | 2007-05-18 | F. Hoffmann-La Roche Ag | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa |
CA2643493C (en) | 2006-03-02 | 2012-07-17 | Chao-Jun Li | 1-naphtholyl tetrahyroisoquinoline derivatives and use thereof as chiral ligands in asymmetric synthesis |
AU2007234968A1 (en) | 2006-03-29 | 2007-10-18 | Novartis Ag | Organic compounds |
JP5223083B2 (ja) | 2006-06-21 | 2013-06-26 | 国立大学法人京都大学 | 血管新生抑制剤 |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
WO2008005368A2 (en) | 2006-06-30 | 2008-01-10 | Abbott Laboratories | Piperazines as p2x7 antagonists |
KR20090024789A (ko) | 2006-07-04 | 2009-03-09 | 얀센 파마슈티카 엔.브이. | 치환 복소환기를 갖는 벤즈이미다졸 카나비노이드 작용제 |
US7872138B2 (en) | 2006-08-07 | 2011-01-18 | Janssen Pharmaceutica Nv | Process for the preparation of substituted-1,2,3,4-tetrahydroisoquinoline derivatives |
US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
NZ575652A (en) | 2006-08-23 | 2011-08-26 | Valeant Pharmaceuticals Int | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
DE102006046922B3 (de) | 2006-09-27 | 2007-11-15 | Julius-Maximilians-Universität Würzburg | Biofilm-hemmende Wirkung sowie anti-infektive Aktivität N,C-verknüpfter Arylisochinoline, deren pharmazeutischen Zusammensetzung und deren Verwendung |
BRPI0718029A2 (pt) | 2006-11-06 | 2013-11-26 | Supergen Inc | Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase |
CN101668746A (zh) | 2007-03-01 | 2010-03-10 | 詹森药业有限公司 | 作为组胺h3受体调节剂的四氢异喹啉化合物 |
US7321064B1 (en) | 2007-03-08 | 2008-01-22 | Cedarburg Pharmaceuticals, Inc. | Preparation of amides of retinoic acid via mixed anhydride and mixed carbonate intermediates |
CA2685860A1 (en) | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
EP2146720A4 (en) | 2007-05-10 | 2012-01-18 | Amr Technology Inc | ARYLOXY- AND HETEROARYLOXY-SUBSTITUTED TETRAHYDROBENZAZEPINE AND THEIR USE FOR THE RECOURSE-INHIBITION OF NOREPINEPHRIN, DOPAMINE AND SEROTONINE |
US7846930B2 (en) | 2007-05-18 | 2010-12-07 | Janssen Pharmaceutica Nv | Diaryl-substituted tetrahydroisoquinolines as histamine H3 receptor and serotonin transporter modulators |
EP2167083B1 (en) | 2007-06-06 | 2015-10-28 | Euthymics Bioscience, Inc. | 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
AR071997A1 (es) | 2008-06-04 | 2010-07-28 | Bristol Myers Squibb Co | Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina |
US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
PE20110063A1 (es) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶,其組合物及使用其之治療方法 |
ES2662072T3 (es) | 2009-05-12 | 2018-04-05 | Albany Molecular Research, Inc. | 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y uso de la misma |
ES2446971T3 (es) | 2009-05-12 | 2014-03-11 | Albany Molecular Research, Inc. | Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso |
ES2528404T3 (es) | 2009-05-12 | 2015-02-10 | Bristol-Myers Squibb Company | Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos |
JP2013526543A (ja) | 2010-05-12 | 2013-06-24 | アッヴィ・インコーポレイテッド | ピロロピリジン系およびピロロピリミジン系キナーゼ阻害薬 |
WO2012024397A2 (en) | 2010-08-17 | 2012-02-23 | Albany Molecular Research, Inc. | 2,5-methano-and 2,5-ethano-tetrahydrobenzazepine derivatives and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
WO2014159501A2 (en) | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Processes for preparing tetrahydroisoquinolines |
-
2005
- 2005-07-15 CN CN200580030990.2A patent/CN101119969B/zh active Active
- 2005-07-15 CN CN201410074721.7A patent/CN103880827B/zh active Active
- 2005-07-15 CA CA2573271A patent/CA2573271C/en active Active
- 2005-07-15 WO PCT/US2005/025193 patent/WO2006020049A2/en active Application Filing
- 2005-07-15 KR KR1020137001614A patent/KR101389246B1/ko active IP Right Grant
- 2005-07-15 AU AU2005274927A patent/AU2005274927B2/en not_active Ceased
- 2005-07-15 NZ NZ552397A patent/NZ552397A/en not_active IP Right Cessation
- 2005-07-15 US US11/183,102 patent/US20060063766A1/en not_active Abandoned
- 2005-07-15 ZA ZA200701232A patent/ZA200701232B/xx unknown
- 2005-07-15 GE GEAP20059847A patent/GEP20094640B/en unknown
- 2005-07-15 EP EP05793999.3A patent/EP1778639B1/en active Active
- 2005-07-15 MX MX2007000428A patent/MX2007000428A/es active IP Right Grant
- 2005-07-15 UA UAA200701576A patent/UA91341C2/ru unknown
- 2005-07-15 JP JP2007521686A patent/JP5007226B2/ja active Active
- 2005-07-15 US US11/183,066 patent/US7541357B2/en active Active
- 2005-07-15 BR BRPI0513359-9A patent/BRPI0513359A/pt not_active IP Right Cessation
- 2005-07-15 RU RU2007105596A patent/RU2388751C2/ru not_active IP Right Cessation
- 2005-07-15 KR KR1020077003549A patent/KR101412339B1/ko active IP Right Grant
-
2006
- 2006-12-26 IL IL180349A patent/IL180349A/en not_active IP Right Cessation
-
2007
- 2007-02-15 NO NO20070877A patent/NO20070877L/no not_active Application Discontinuation
-
2008
- 2008-10-16 US US12/252,823 patent/US8227486B2/en active Active
-
2009
- 2009-04-02 US US12/417,598 patent/US8236796B2/en active Active
-
2012
- 2012-04-05 JP JP2012086151A patent/JP5552137B2/ja active Active
- 2012-07-02 US US13/540,446 patent/US8741901B2/en active Active
-
2014
- 2014-05-02 US US14/268,753 patent/US9085531B2/en active Active
- 2014-12-23 HK HK14112805.4A patent/HK1199253A1/xx not_active IP Right Cessation
-
2015
- 2015-06-12 US US14/737,897 patent/US9499531B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0513359A (pt) | tetraidroisoquinolinas substituìdas por arila e heteroarila e uso destes para bloquear a recaptação de norepinefrina, dopamina, e serotonina | |
AU2021201244B2 (en) | Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators | |
US10517858B2 (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as PIM kinase inhibitors | |
ES2250689T3 (es) | 1h-pirido(4,3-b)indoles terapeuticos. | |
JP5539190B2 (ja) | チアゾロピリミジン類及びホスファチジルイノシトール−3キナーゼのインヒビターとしてのそれらの使用 | |
UA123794C2 (uk) | Нові похідні піперидинілу, спосіб їхнього отримання та фармaцевтичні композиції, що їх містять | |
KR101764556B1 (ko) | 디아자카르바졸 및 사용 방법 | |
CN108602805A (zh) | Mnk1和mnk2的异吲哚啉、氮杂异吲哚啉、二氢茚酮和二氢氮杂茚酮抑制剂 | |
KR101286796B1 (ko) | 1,4-디히드로피리딘-융합된 헤테로사이클, 그의 제조 방법,용도 및 그를 함유하는 조성물 | |
TW201247665A (en) | Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent | |
CO6251238A2 (es) | Tetrahidrobenzo-1,4-diacepinas arilo - y heteroarilo - sustituidas y su uso para bloquear la recaptacion de norepinefrina dapamina y serotanina | |
PT2834248E (pt) | Novos derivados da tienopirimidina, processos para a sua preparação e sua utilização terapêutica | |
CA2772989A1 (en) | Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer | |
US20190031685A1 (en) | Heteroaryl compounds and methods of use thereof | |
WO2006051410A1 (en) | Azabenzoxazoles for the treatment of cns disorders | |
JP2019524658A (ja) | 置換三環式複素環化合物及びその用途 | |
US20060166974A1 (en) | Azabenzoxazoles for the treatment of CNS disorders | |
Milen et al. | Synthesis of New Thienopyridine Derivatives by a Reaction of 4‐(Methylsulfanyl)‐6, 7‐dihydrothieno [3, 2‐c] pyridine with Amino Acids | |
WO2022194087A1 (en) | Modified proteins and protein binders | |
WO2023107870A1 (en) | Inhibitors of fibroblast growth factor receptor kinases | |
WO2024073502A1 (en) | Heterocyclic compounds as e3 ligase inhibitors | |
OA19533A (en) | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: BRISTOL-MYERS SQUIBB COMPANY (US) , ALBANY MOLECUL |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |